July 27, 2020 / 6:25 AM / 19 days ago

AstraZeneca to pay up to $6 bln in new cancer drug deal with Daiichi

July 27 (Reuters) - British drugmaker AstraZeneca could pay up to $6 billion to Japan's Daiichi Sankyo as part of a new collaboration to develop and market a type of potential cancer treatment for multiple tumour types.

AstraZeneca will pay Daiichi an upfront payment of $1 billion for DS-1062, a type of antibody drug conjugate (ADC). (Reporting by Pushkala Aripaka in Bengaluru; Editing by Saumyadeb Chakrabarty)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below